# Atrium Therapeutics (RNA) — Analyst Forecast

RNA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rna/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 4 | 0 | 0 | 4 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 14, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Aug 6, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $25.00 |
| Jun 18, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | $25.00 |
| May 15, 2026 | Leerink Partners | Initiated Coverage | Outperform | $25.00 |
| May 1, 2026 | HC Wainwright & Co. |  | Neutral | — |
| Mar 11, 2026 | Wells Fargo | Initiated Coverage | Overweight | $25.00 |

## Frequently Asked Questions

### Is RNA a buy, sell, or hold?

Analysts covering Atrium Therapeutics currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on RNA?

On Aug 14, 2026, HC Wainwright & Co. maintained Atrium Therapeutics at Buy with a price target of $25.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).